Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

ACIU

ACIU News

Newswire

14:53

Maintaining 'Buy' Rating on AC Immune's PD Trial Progress with ACI-7104.056

04:07

AC Immune shares jump 13.98% premarket after positive Phase 2 data shows Parkinson's progression slowdown potential.

16:43

AC Immune shares rise 14.70% after-hours after positive Phase 2 data for ACI-7104.056 shows potential to slow Parkinson’s progression via alpha-synuclein immunotherapy.

13:10

AC Immune Trial Shows Early Signs of Immunotherapy's Potential to Slow Parkinson's Disease Progression

10:25

AC Immune shares rise 14.33% intraday after Phase II VacSYn trial shows ACI-7104.056 may slow Parkinson's progression with 100% immunogenicity and no serious adverse events.

View More

About ACIU

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More